Acetyl Tetrapeptide-5
Also referenced as: Eyeseryl
An acetylated cosmetic peptide marketed in under-eye products.
- Evidence grade
- EExperimental / Limited Evidence
Experimental / Limited Evidence
- Regulatory status
- Not FDA Approved
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- October 27, 2026
Overview
An acetylated cosmetic peptide marketed in under-eye products.
A cosmetic ingredient, not an FDA-approved anti-aging drug. Cosmetic marketing and ingredient safety reviews do not establish injectable safety or therapeutic approval.
Changes in puffiness appearance do not establish treatment of medical edema.
Why It's Being Studied
- Under-eye appearance
- Cosmetic formulation
Mechanism of Action
Proposed mechanisms concern fluid-related appearance and glycation, but these remain cosmetic hypotheses rather than established treatment mechanisms.
Proposed mechanisms concern fluid-related appearance and glycation, but these remain cosmetic hypotheses rather than established treatment mechanisms. Changes in puffiness appearance do not establish treatment of medical edema.
Skin remodelling and the hair cycle
Tap each stage to see what happens.
Background: Skin & Hair Research
Skin and hair research looks at collagen synthesis, wound closure, pigmentation and the hair-follicle cycle.
Topical cosmetic research is often industry-funded and small. Injected use of cosmetic peptides has little human data.
Research Areas & Routes Studied
- Under-eye appearance
- Cosmetic formulation
- Topical cosmetic formulations
Evidence Summary
Robust independently replicated trials of this ingredient alone have not been established.
Higher tiers carry more weight. Filled tiers have evidence for Acetyl Tetrapeptide-5; tap to read it.
No evidence at this tier is summarised for Acetyl Tetrapeptide-5. Absence of data is not evidence of safety or benefit.
2 cited sources.
- Narrative review1
- Regulatory document1
Evidence limitations
- Robust independently replicated trials of this ingredient alone have not been established.
Reported Adverse Events in Research
- Eye-area irritation may depend on the product; unexplained swelling should not be treated as a cosmetic peptide deficiency.
Limitations of Current Evidence
- Changes in puffiness appearance do not establish treatment of medical edema.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Was the product topical or injected?
- Were results measured by instruments or by photos and self-assessment?
- Who funded the study?
- Cosmetic claims face a lower evidence bar than medical claims.
- Pigmentation-affecting compounds carry documented risks, including changes in moles.
- Anagen
- The active growth phase of a hair follicle.
- Dermis
- The skin layer beneath the surface that holds collagen.
- Melanocortin
- A hormone family that affects pigmentation and appetite.
Compare With Other Compounds
| Acetyl Tetrapeptide-5 | GHK-Cu | |
|---|---|---|
| Evidence grade | E — Experimental / Limited Evidence | C — Early Human Research |
| Regulatory status | Not FDA Approved | Not FDA Approved |
| Human data | No | Limited |
| Clinical trials | None identified | None identified |
| Research routes | Topical cosmetic formulations | Topical, Intradermal (cosmetic research) |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Narrative review
Cosmetic peptide research and delivery limitations
- Regulatory document
FDA: cosmetics are not preapproved medicines